China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

Shi, Yuankai; Sun, Yan; Yu, Jinming; Ding, Cuimin; Wang, Ziping; Wang, Changli; Wang, Dong; Wang, Cunde; Wang, Zheng; Wang, Mengzhao; Zhi, Xiao; Lu, You; Feng, Jifeng; Liu, Yunpeng; Liu, Xiaoqing; Liu, Wei; Wu, Gang; Li, Xiaomei; Li, Kai; Li, Enxiao; Li, Wei; Chen, Gongyan; Chen, Zhengtang; Yu, Ping; Wu, Ning; Wu, Milu; Xiao, Wenhua; Zhang, Li; Zhang, Yiping; Zhang, Shucai; Yang, Shujun; Song, Xuejiao; Lin, Dongmei; Luo, Rong; Li, Shan; Zhou, Caicun; Zhou, Zongmei; Zhao, Qiu; Hu, Chengping; Hu, Yi; Guo, Qisen; Chang, Jianhua; Huang, Cheng; Zhang, Xuan; Han, Baohui; Han, Xiaohong; Jia, Bo; Han, Ying; Huang, Yu Chen

doi:10.1111/ajco.12608

Cited by 50 publications

(56 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…China Food and Drug Administration (CDFA) [5]. Compared with the gefitinib, icotinib shows similar clinical therapeutic efficacy and better safety [6].…”

Section: Ivyspring International Publishermentioning

confidence: 99%

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis

et al. 2020

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) wild-type is intrinsic resistance to EGFR-tyrosine kinase inhibitors (TKIs). In this study, we assessed whether the combination of bisdemethoxycurcumin (BDMC) and icotinib could surmount primary EGFR-TKI resistance in NSCLC cells and investigated its molecular mechanism. Results showed that the combination of BDMC and icotinib produced potently synergistic growth inhibitory effect on primary EGFR-TKI-resistant NSCLC cell lines H460 (EGFR wild-type and K-ras mutation) and H1781 (EGFR wild-type and Her2 mutation). Compared with BDMC or icotinib alone, the two drug combination induced more significant apoptosis and autophagy via suppressing EGFR activity and interaction of Sp1 and HDCA1/HDCA2, which was accompanied by accumulation of reactive oxygen species (ROS), induction of DNA damage, and inhibition of cell migration and invasion. ROS inhibitor (NAC) and autophagy inhibitors (CQ or 3-MA) partially reversed BDMC plus icotinib-induced growth inhibitory effect on the NSCLC cells. Meanwhile, co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability. Also, 3-MA or CQ can abate the combination treatment-induced apoptosis and DNA damage, suggesting that there is crosstalk between different signaling pathways in the effect produced by the combination treatment. Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib.

show abstract

“…China Food and Drug Administration (CDFA) [5]. Compared with the gefitinib, icotinib shows similar clinical therapeutic efficacy and better safety [6].…”

Section: Ivyspring International Publishermentioning

confidence: 99%

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In China, the standard for advanced NSCLC treatment is comprehensive treatment, mainly using systemic therapy . According to the China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version) , EGFR tyrosine kinase inhibitors (TKIs; drugs approved by the China Food and Drug Administration [CFDA] include gefitinib [2010], erlotinib [2017], afatinib [2017], and icotinib [2014]) could be used as the first‐line systemic therapy in patients with sensitizing EGFR mutations that are documented before the application of first‐line therapy. For patients with locally advanced or metastatic NSCLC who have ALK or ROS1 rearrangements, crizotinib (approved in 2013) is recommended as the first‐line therapy.…”

Section: Current Status Of Lung Cancer Management In Chinamentioning

confidence: 99%

“…The recommended first‐line chemotherapy regimens for patients with an Eastern Cooperative Oncology Group performance score (ECOG PS) of 0–2 include etoposide + cisplatin, etoposide + carboplatin, irinotecan + cisplatin, or irinotecan + carboplatin. If treatment fails, patients with recurrence or progression within 3 months are encouraged to participate in clinical trials; topotecan, irinotecan, gemcitabine, or paclitaxel are considered for patients with recurrence within 3–6 months .…”

Section: Current Status Of Lung Cancer Management In Chinamentioning

confidence: 99%

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Lü

Yang

2019

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Epidermal growth factor receptor (EGFR) gene mutation detection in patients suffering from lung cancer is the key step before EGFR tyrosine kinase inhibitor (TKI) therapy, which only targets potential beneficiaries with a specific gene mutant subtype, e.g., exon 21 L858R, exon 19 deletion, and exon 20 S768I.Therefore, the relevant consensus and guidelines in China have emphasized the necessity and importance of assessment on EGFR gene status, the standardization of experimental operations, the acquisition and processing of specimens, and the selection of methodologies and scenarios of implementation due to the high percentage of prevalence of EGFR mutations in non‐small cell lung cancer (NSCLC) patients in China (approximately 60%) compared to that of Caucasians . Along with the clinical application of third‐generation EGFR TKIs, such as osimertinib, in clinical practice, it is optimal to obtain sufficient cancer tissue by rebiopsy from recurrent lesions for essential pathology diagnosis and biomarker measurement, including threonine‐to‐methionine substitution at position 790 of the EGFR gene (T790M), which resulted from EGFR TKI resistance during disease progression and is probably sensitive to third‐generation EGFR TKIs .…”

Section: Introductionmentioning

confidence: 99%

EGFR T790M detection in formalin‐fixed paraffin‐embedded tissues of patients with lung cancer using RNA‐based in situ hybridization: A preliminary feasibility study

Shi

et al. 2019

Thoracic Cancer

Self Cite

View full text Add to dashboard Cite

Background Following drug resistance in patients with lung cancer treated by EGFR TKIs, a biopsy is required to obtain sufficient cancer tissue for T790M detection in order to select potential beneficiaries suitable for third‐generation EGFR TKIs, such as osimertinib. The purpose of this study was to explore the feasibility of using a new in situ analysis technique based on RNA target sequences to detect EGFR T790M in lung cancer. Methods A total of 28 formalin‐fixed paraffin‐embedded (FFPE) samples from 24 lung adenocarcinoma patients archived in Peking Union Medical College Hospital from 2015 to 2016 were collected. The BaseScope T790M detection technique by in situ hybridization on FFPE slides was used to analyze the mutation of EGFR T790M, and then the results were compared with the data acquired by Scorpions ARMS assay, which is the so‐called gold standard for EGFR gene mutation testing. The sensitivity and specificity of the BaseScope T790M detection technique were preliminarily evaluated. Results Of the 28 FFPE specimens, the average proportion of T790M‐positive cells was 35.78% ± 17.68% in 18 samples with EGFR T790M, confirmed by Scorpions ARMS assay, Compared with real‐time PCR assay, the sensitivity and specificity of BaseScope T790M were all 100% in our cohort. Conclusion BaseScope T790M assay could be completed on only one FFPE slide and the visualized molecular result overplayed with histomorphological information perfectly, so it may be the alternative method for EGFR T790M evaluation. BaseScope assay has potential clinical utility, and it will be necessary to carry out validation with a large number of cases.

show abstract

China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

Cited by 50 publications

References 65 publications

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

EGFR T790M detection in formalin‐fixed paraffin‐embedded tissues of patients with lung cancer using RNA‐based in situ hybridization: A preliminary feasibility study

Contact Info

Product

Resources

About